BBNX Beta Bionics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: BBNX

Price (delayed)

$22.19

Market cap

$998.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.64

Enterprise value

$960.42M

?
Relative Growth: Rel. Growth: 71
Relative Strength: Rel. Strength: 88
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 27
Highlights
The company's gross profit has surged by 65% YoY and by 10% QoQ
The revenue has soared by 53% YoY and by 8% from the previous quarter
Beta Bionics's EPS has soared by 70% YoY but it has decreased by 9% from the previous quarter
BBNX's quick ratio is down by 43% year-on-year and by 18% since the previous quarter
The equity has contracted by 15% YoY and by 5% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: https://www.betabionics.com
Peers: ABT MDT ISRG SYK

Key stats

What are the main financial stats of BBNX

BBNX stock price

How has the Beta Bionics stock price performed over time
Intraday
-2.72%
1 week
0.05%
1 month
16.48%
1 year
-2.97%
YTD
-27.17%
QTD
41.61%

Financial performance

How have Beta Bionics's revenue and profit performed over time
Revenue
$119.01M
Gross profit
$69.4M
Operating income
-$83.02M
Net income
-$72.97M
Gross margin
58.3%
Net margin
-61.3%
The company's gross profit has surged by 65% YoY and by 10% QoQ
The revenue has soared by 53% YoY and by 8% from the previous quarter
The net margin is up by 35% YoY
The operating income has declined by 33% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does BBNX's price correlate with its fundamentals

Growth

What is Beta Bionics's growth rate over time

Valuation

What is Beta Bionics stock price valuation
P/E
N/A
P/B
3.86
P/S
8.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.07
Beta Bionics's EPS has soared by 70% YoY but it has decreased by 9% from the previous quarter
The P/B is 32% higher than the last 4 quarters average of 3.0
The equity has contracted by 15% YoY and by 5% from the previous quarter
The revenue has soared by 53% YoY and by 8% from the previous quarter
The price to sales (P/S) is 7% more than the last 4 quarters average of 8.0

Efficiency

How efficient is Beta Bionics business performance
The return on equity has surged by 87% year-on-year but it has declined by 14% since the previous quarter
Beta Bionics's ROS has increased by 35% YoY
The ROIC has grown by 29% YoY but it has contracted by 16% from the previous quarter
BBNX's ROA is up by 28% YoY but it is down by 13% QoQ

Dividends

What is BBNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBNX.

Financial health

How did Beta Bionics financials performed over time
BBNX's quick ratio is down by 43% year-on-year and by 18% since the previous quarter
The company's current ratio fell by 40% YoY and by 17% QoQ
The debt is 97% less than the equity
Beta Bionics's debt to equity has surged by 50% YoY
The equity has contracted by 15% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.